Personalized Approach Shows Survival Benefit in Esophageal Adenocarcinoma
Results of a clinical study called PANGEA (Personalized ANtibodies for GastroEsophageal Adenocarcinoma) found survival benefits for patients when compared to [...]
Best Birthday Gift
A message from ECAN's founder: My husband’s birthday came this week. And this year, for the first time since he [...]
Immunotherapy Breakthroughs for Esophageal Cancer Patients
The early results of two large, Phase III clinical trials of the immunotherapy Opdivo (nivolumab) showed significant survival benefits for [...]
Barrett’s Esophagus and Esophageal Adenocarcinoma can run in Families
The familial connection is one of the Strongest Indicators of Risk according to Experts. ECAN spoke with the Leading Researcher [...]
FDA calls New Screening Test Using DNA to Detect Esophageal Cancer a Breakthrough Device
First Time the FDA has given Breakthrough Designation for a Device Targeting Diseases of the Esophagus. Lucid Diagnostics' EsoGuard™ Esophageal [...]
#GivingTuesday Gratitude
ECAN thanks everyone who donated or raised funds to support our medical research campaign on #GivingTuesday! You and the rest [...]
ECAN Advocates Convince Congress to Include Esophageal Cancer in a Multi-Million Dollar Research Fund
For the second year in a row, thousands of ECAN advocates made their voices heard and convinced lawmakers in the [...]
First Patient Dosed in Phase 3 Trial Testing Tyvyt as First-line Therapy for Esophageal Cancer
First Esophageal Cancer patient is dosed in Phase 3 clinical trial using immune checkpoint inhibitor Tyvyt (sintilimab injection), in [...]
Esophageal Cancer Genome
ECAN’s President and CEO Mindy Mintz Mordecai recently had the opportunity to interview Dr. Adam Bass, co-chair of the [...]